Stamey T A, Kabalin J N, Ferrari M, Yang N
Division of Urology, Stanford University Medical Center, California 94306-5118.
J Urol. 1989 May;141(5):1088-90. doi: 10.1016/s0022-5347(17)41177-3.
Serum prostate specific antigen was determined (Yang polyclonal radioimmunoassay) in 45 patients after anti-androgen therapy for stage D2, untreated adenocarcinoma of the prostate. Of the patients 9 per cent had undetectable prostate specific antigen levels and 22 per cent were within the normal range (0.0 to 2.5 ng. per ml.), with a mean interval of 2 years since introduction of therapy. Multiple prostate specific antigen values following anti-androgen therapy were available in 36 of 45 patients. The majority of the patients demonstrated an initial, often dramatic decrease in prostate specific antigen levels during the first 6 months after introduction of therapy. After 6 months 21 of 29 patients (72 per cent) had increasing prostate specific antigen levels. Data suggest that serum prostate specific antigen determination 6 months after introduction of therapy is capable of distinguishing patients with a favorable and persisting response to anti-androgen therapy from those in whom a limited response can be expected.
对45例D2期未经治疗的前列腺腺癌患者进行抗雄激素治疗后，采用杨（氏）多克隆放射免疫测定法测定血清前列腺特异性抗原。这些患者中，9%的患者前列腺特异性抗原水平检测不到，22%的患者前列腺特异性抗原水平在正常范围内（0.0至2.5纳克/毫升），自开始治疗以来平均间隔时间为2年。45例患者中有36例有抗雄激素治疗后的多个前列腺特异性抗原值。大多数患者在开始治疗后的头6个月内，前列腺特异性抗原水平最初通常会急剧下降。6个月后，29例患者中有21例（72%）前列腺特异性抗原水平升高。数据表明，治疗开始6个月后测定血清前列腺特异性抗原能够区分对抗雄激素治疗有良好且持续反应的患者和预期反应有限的患者。
